Blog

25 January 2022 - Registration now open for 1 February “Early Insights” webinar. Public comment period now open until 22 ...

9 November 2021 - Public comment period now open until 8 December 2021; requests to make oral comment during public ...

4 November 2021 - Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic ...

20 October 2021 - Independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a ...

16 September 2021 - Public comment period now open until 14 October 2021; requests to make oral comment during public ...

10 September 2021 - While eculizumab and efgartigimod each provide important health benefits, both would need to be priced more than ...

18 August 2021 - Public comment period now open until 15 September 2021; requests to make oral comment during public meeting ...

22 July 2021 - Public comment period now open until 18 August 2021; requests to make oral comment during public meeting ...

9 July 2021 - Evidence demonstrates the JAK inhibitors abrocitinib and upadacitinib are effective treatments for atopic dermatitis, but safety concerns ...

14 May 2021 - Public comment period now open until 11 June 2021; requests to make oral comment during public meeting ...

11 May 2021 - Independent appraisal committee unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel ...

16 April 2021 - For belimumab and voclosporin, independent appraisal committee votes highlight the importance of several potential benefits of both ...

28 January 2021 - Other than a proven ability to reduce the need for intravenous iron supplements, the evidence is insufficient ...

22 January 2021 - The evidence suggests that inclisiran can substantially lower LDL-C with limited safety concerns, and with a ...